Head of the Genomics Applications Laboratory, Core Research Facility, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Microbiol Spectr. 2022 Aug 31;10(4):e0073622. doi: 10.1128/spectrum.00736-22. Epub 2022 Jun 27.
COVID-19 is caused by SARS-CoV-2, several virulent variants of which have emerged since 2019. More than 529 million people have been infected, and at least 6 million have died. Our aim was to develop a fast, accurate, low-cost method for detecting and identifying newly emerging variants of concern (VOCs) that could pose a global threat. The 341-bp DNA sequence of a specific region of the SARS-CoV-2's spike protein was amplified by a one-step PCR on RNA samples from 46 patients. The product was sequenced using next-generation sequencing (NGS). DNA sequences from seven genomes, the original Wuhan isolate and six different representative variants obtained from the GISAID website, were used as references. Complete whole-genome sequences from local isolates were also obtained from the GISAID website, and their RNA was used for comparison. We used an amplicon-based NGS method (termed VOC-NGS) for genotyping and successfully identified all 46 samples. Fifteen (32.6%) were like the original isolate. Twenty-seven were VOCs: nine (19.5%) Alpha, eight (19%) Delta, six (14%) Beta, and four (8.7%) Omicron. Two were variants of interest (VOI): one (2%) Kappa and one (2%) Zeta. Two samples were mixtures of two variants, one of Alpha and Beta and one of Alpha and Delta. The Spearman correlation between whole-genome sequencing (WGS) and VOC-NGS was significant ( < 0.001) with perfect agreement (Kappa = 0.916) for 36/38 (94.7%) samples with VOC-NGS detecting all the known VOCs. Genotyping by VOC-NGS enables rapid screening of high-throughput clinical samples that includes the identification of VOCs and mixtures of variants, at lower cost than WGS. The manuscript described SARS-Cov-2 genotyping by VOC-NGS, which presents an ideal balance of accuracy, rapidity, and cost for detecting and globally tracking VOCs and some VOI of SARS-CoV-2. A large number of clinical samples can be tested together. Rapid introduction of new mutations at a specific site of the spike protein necessitates efficient strain detection and identification to enable choice of treatment and the application of vaccination, as well as planning public health policy.
新型冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)引起,自 2019 年以来已出现多种高致病性变异株。目前已有超过 5.29 亿人感染,至少 600 万人死亡。我们的目标是开发一种快速、准确、低成本的方法,用于检测和识别可能构成全球威胁的新出现的关注变异株(VOC)。从 46 名患者的 RNA 样本中,通过一步法 PCR 扩增 SARS-CoV-2 刺突蛋白特定区域的 341bp DNA 序列。使用下一代测序(NGS)对产物进行测序。使用来自七个基因组的 DNA 序列作为参考,包括原始武汉分离株和从 GISAID 网站获得的六个不同的代表性变体。还从 GISAID 网站获得了本地分离株的完整全基因组序列,并将其 RNA 用于比较。我们使用基于扩增子的 NGS 方法(称为 VOC-NGS)进行基因分型,成功鉴定了所有 46 个样本。其中 15 个(32.6%)与原始分离株相似。27 个为 VOC:9 个(19.5%)为 Alpha,8 个(19%)为 Delta,6 个(14%)为 Beta,4 个(8.7%)为 Omicron。2 个为关注变异株(VOI):1 个(2%)为 Kappa,1 个(2%)为 Zeta。有两个样本为两种变异株的混合物,一个为 Alpha 和 Beta,一个为 Alpha 和 Delta。VOC-NGS 与全基因组测序(WGS)之间的 Spearman 相关性具有统计学意义(<0.001),一致性完美(Kappa=0.916),36/38(94.7%)个具有 VOC-NGS 检测到所有已知 VOC 的样本。VOC-NGS 基因分型可快速筛选高通量临床样本,包括 VOC 和变异株混合物的鉴定,成本低于 WGS。本研究描述了通过 VOC-NGS 对 SARS-CoV-2 进行基因分型,在检测和全球追踪 SARS-CoV-2 的 VOC 和一些 VOI 方面,该方法在准确性、速度和成本方面具有理想的平衡。大量临床样本可同时进行检测。刺突蛋白特定部位的新突变迅速出现,需要进行有效的菌株检测和鉴定,以选择治疗方法和接种疫苗,并制定公共卫生政策。